Heska (NASDAQ:HSKA) Shares Down 10.4% Following Analyst Downgrade
Heska Corp (NASDAQ:HSKA) traded down 10.4% during trading on Thursday after Canaccord Genuity lowered their price target on the stock from $95.00 to $75.00. Canaccord Genuity currently has a buy rating on the stock. Heska traded as low as $63.41 and last traded at $64.17, 852,960 shares traded hands during mid-day trading. An increase of 913% from the average session volume of 84,201 shares. The stock had previously closed at $71.61.
A number of other research analysts also recently commented on the company. Guggenheim assumed coverage on Heska in a research note on Thursday, May 23rd. They issued a “neutral” rating on the stock. ValuEngine upgraded Heska from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Finally, BidaskClub downgraded Heska from a “hold” rating to a “sell” rating in a research note on Saturday, August 31st. Two research analysts have rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. Heska has an average rating of “Hold” and an average price target of $91.00.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its position in shares of Heska by 0.6% in the second quarter. BlackRock Inc. now owns 1,074,360 shares of the medical research company’s stock worth $91,503,000 after buying an additional 6,904 shares during the last quarter. FMR LLC lifted its position in shares of Heska by 2.0% in the first quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock worth $38,616,000 after buying an additional 8,870 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Heska by 1.1% in the second quarter. Vanguard Group Inc. now owns 448,105 shares of the medical research company’s stock worth $38,166,000 after buying an additional 5,019 shares during the last quarter. Redmile Group LLC lifted its position in shares of Heska by 14.3% in the first quarter. Redmile Group LLC now owns 226,013 shares of the medical research company’s stock worth $19,238,000 after buying an additional 28,300 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Heska by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 219,430 shares of the medical research company’s stock worth $18,893,000 after buying an additional 1,253 shares during the last quarter. Hedge funds and other institutional investors own 89.02% of the company’s stock.
Heska (NASDAQ:HSKA) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. Heska had a return on equity of 6.35% and a net margin of 1.93%. The company had revenue of $28.15 million during the quarter, compared to analysts’ expectations of $29.19 million. As a group, equities analysts anticipate that Heska Corp will post 0.05 earnings per share for the current year.
About Heska (NASDAQ:HSKA)
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Featured Story: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.